Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

NCT02078843 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT02078843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02078843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2014
Completion date
August 31, 2016
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine tumors